Rare Disease AdvisorStudy Identifies Predictors of Frailty in ATTR-CM

⚠️ Small Study / Early Comparative Evidence

Researchers evaluated 68 Australian patients with transthyretin amyloid cardiomyopathy to identify routinely available clinical and biomarker characteristics associated with frailty. Frailty, defined as a Clinical Frailty Scale score of at least 5, became more prevalent with advancing National Amyloidosis Centre stage and NYHA functional class. Multivariable analysis identified more advanced disease stage and functional limitation, rather than age or interventricular septal thickness, as independent frailty correlates. The small retrospective study requires validation before these measures can serve as surrogate frailty markers.

Clinical Considerations

• Frailty prevalence increased with advancing National Amyloidosis Centre stage and worsening NYHA functional class.
• NAC stages II and III were independently associated with frailty after multivariable analysis.
• NYHA classes III and IV were also independently associated with frailty.
• Age was not independently associated with frailty despite the cohort comprising patients aged 74 to 84 years.
• Interventricular septal thickness was likewise not independently associated with frailty.
• The study was limited to 68 patients, 88% of whom were men, restricting generalizability.

Practice Applications

• Recognize frailty as a relevant clinical feature accompanying more advanced ATTR-CM and greater functional impairment.
• Consider disease stage and NYHA class as potential frailty signals alongside direct clinical assessment.
• Avoid interpreting age alone as a surrogate for frailty in patients with ATTR-CM.
• Interpret the proposed surrogate markers cautiously until validated in larger and more diverse populations.